Rufinamide

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathies

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Use as a concomitant therapy with other antiepileptic drugs to treat tonic and atonic seizures in patients with Lennox-Gastaut syndrome who have not responded sufficiently to other antiepileptic drugs
Product first approved 2013PMDA
EU
  • Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Epilepsy
NCT00448539 · Eisai Inc.
2007-03-15 – 2010-05-14 · Refractory Partial Onset Seizures
What this study did
NCT04558580 · University of South Alabama
2006-04 – 2008-12 · Refractory Partial Seizures
What this study did
Lennox-Gastaut Syndrome
NCT01151540 · Eisai Co., Ltd.
2010-11 – 2013-08 · Lennox-Gastaut Syndrome
What this study did
Phase 2 (2)
Other / comorbidity
NCT02095899 · University of Zurich
2014-03 – 2015-05 · Peripheral Nerve Injuries, Pain
What this study did
NCT00595231 · Biotie Therapies Inc.
2008-03 – 2008-10 · Generalized Anxiety Disorder
What this study did
Phase 1 (2)
Epilepsy
NCT02332174 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2014-03 – 2014-06 · Seizures
What this study did
Other / comorbidity
NCT06740825 · Daiichi Sankyo
2024-10-29 – 2024-12-09 · Healthy Subjects
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rufinamide: this drugApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001).
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.